☆ 4.5 Editorial Material

Waiting for JAK inhibitor safety data

RMD OPEN (2022)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Kevin L. Winthrop et al.

Summary: In patients with moderately to severely active rheumatoid arthritis, the safety and tolerability of Filgotinib were good, with a lower incidence of infections in the Filgotinib 200 mg dose group compared to placebo during long-term treatment.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Farzin Khosrow-Khavar et al.

Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Meeting Abstract Rheumatology

RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3B/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS

C. Charles-Schoeman et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden

Viktor Molander et al.

Summary: This study found a strong association between clinical RA disease activity and the risk of VTE, with RA patients having a significantly higher risk compared to non-RA individuals. Additionally, the risk of VTE in RA patients increased with higher disease activity levels, indicating that RA disease activity can be used as an additional tool for stratifying VTE risk in these patients.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Risk of Venous Thromboembolism Associated With Methotrexate Versus Hydroxychloroquine for Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study

Mengdong He et al.

Summary: In this observational study of elderly RA patients, methotrexate users had a higher incidence of VTE compared to hydroxychloroquine users, while the all-cause mortality rates were similar between the two groups.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

Add to Collection

Review Rheumatology

2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

Elena Nikiphorou et al.

Summary: The recommendations focus on empowering patients to become active partners in their care, including patient education and key self-management interventions. Patient organizations and healthcare providers play a crucial role in promoting and signposting patients to available resources, emphasizing the importance of digital healthcare in supporting self-management.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Review Rheumatology

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Peter Nash et al.

Summary: The use of Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases has been extensively reviewed to provide guidance on efficacy and safety. A consensus statement was formed by an expert committee, evaluating 26 key points in six areas, with high levels of agreement and evidence-based recommendations. This consensus offers valuable insights for the practical management of JAKi in clinical practice.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Review Pharmacology & Pharmacy

Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?

Masayoshi Harigai et al.

DRUGS (2020)

Add to Collection

Article Medicine, General & Internal

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis A Cohort Study

Michael D. George et al.

ANNALS OF INTERNAL MEDICINE (2020)

Add to Collection

Article Rheumatology

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Katerina Chatzidionysiou et al.

RMD OPEN (2020)

Add to Collection

Article Rheumatology

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Stanley B. Cohen et al.

RMD OPEN (2020)

Add to Collection

Article Rheumatology

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Josef S. Smolen et al.

JOURNAL OF RHEUMATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants

Elizabeth R. C. Millett et al.

BMJ-BRITISH MEDICAL JOURNAL (2018)

Add to Collection

Article Endocrinology & Metabolism

Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys

Peter Ueda et al.

LANCET DIABETES & ENDOCRINOLOGY (2017)

Add to Collection

Article Rheumatology

Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events

D. H. Solomon et al.

ARTHRITIS & RHEUMATOLOGY (2015)

Add to Collection

Article Rheumatology

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

Anja Strangfeld et al.

ARTHRITIS RESEARCH & THERAPY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.